Bortezomib and Bevacizumab ("BB-mib-mab") in Patients With Advanced or Recurrent Renal Cell Cancer (RCC)

Inclusion Criteria: * Distant metastatic (TX NX M1) or locally recurrent renal cell carcinoma not amenable to cure by surgical or other means * Measurable or non-measurable (evaluable) disease either on imaging scan or physical examination * Pathological confirmation of the diagnosis of renal cell carcinoma either during prior nephrectomy or by biopsy of a primary or metastatic lesion - provision of a paraffin-embedded tissue block to confirm the diagnosis and allow molecular correlate assessment is required. * ECOG performance status 0 or 1. * Patients must have an AGC of greater than or equal to 1,500/mm3 and a platelet count of greater than or equal to 100,000/mm3. These tests must be obtained within 28 days of registration. * Patients must have a calculated or measured creatinine clearance greater than or equal to 40 ml/min obtained within 28 days prior to registration. * Voluntary written informed consent before performance of any study-related procedure not part of normal medical care * Female subject is either post-menopausal or surgically sterilized or willing to use an acceptable method of birth control (ie, a hormonal contraceptive, intra-uterine device, diaphragm with spermicide, condom with spermicide, or abstinence) for the duration of the study. * Male subject agrees to use an acceptable method of contraception for the duration of the study. * May have been treated with interleukin and/or interferon but must not have had more than one line of prior cytotoxic chemotherapy * May have had up to one biologic therapy provided they have not had bortezomib or bevacizumab * May have had up to 2 prior vaccine therapies * May have been treated with radiation therapy, provided there are measurable or evaluable lesions outside the field of radiation * May have had radiation provided the patient has recovered from the side effects of the therapy (typically 2 weeks after final fraction) and less than 30% of the total bone marrow has been irradiated Exclusion Criteria: * Brain metastases or history of brain metastases * History of deep vein thrombosis or thromboembolic disease within 1 year or requiring ongoing anticoagulant therapy * History of stroke or myocardial infarction within six months * Other major illnesses likely to limit survival including poorly controlled hypertension (BP \> 150/100 mmHg) or symptomatic or clinically significant peripheral vascular disease or angina pectoris * Unstable angina * New York Heart Association (NYHA) Grade II or greater congestive heart failure * Urine protein:creatinine ratio greater than or equal to 1.0 at screening * Evidence of bleeding diathesis or coagulopathy. * Major surgical procedure, open biopsy, significant traumatic injury within 28 days prior to Day 0, or anticipation of need for major surgical procedure during the course of the study * Minor surgical procedures, fine needle aspirations or core biopsies within 7 days prior to Day 0 * Pregnant (positive pregnancy test) or lactating; confirmation that female subject is not pregnant by a negative serum beta-human chorionic gonadotropin (beta-hCG) pregnancy test result obtained during screening. Pregnancy testing is not required for post-menopausal or surgically sterilized women. * Inability to comply with study and/or follow-up procedures * History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 28 days prior to Day 0 * Serious, non-healing wound, ulcer, or bone fracture * Neuropathy at baseline \> grade 1 * Patient has received other investigational drugs within 14 days before enrollment * Patient has hypersensitivity to bevacizumab, bortezomib, boron or mannitol